Developments in personalized therapy for metastatic renal cell carcinoma.

Ryo FujiwaraSusumu KageyamaTakeshi Yuasa

Published in: Expert review of anticancer therapy (2022)

ICIs are rapidly being introduced for the treatment of mRCC. Currently, most patients are treated with a combination of ICIs or a combination of ICI and TKIs. In order to develop optimal personalized treatment for our patients, it is necessary for the physicians who treat mRCC patients to possess in-depth knowledge of these new therapeutic tools.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
healthcare
primary care
patient reported outcomes
metastatic renal cell carcinoma
patient reported
smoking cessation